Pancare ‘Support, Save and Win’ promotion now has a winner
Thank you to all of our supporters who entered into our national Pancare, ‘Support, Save and Win’ promotion to raise much-needed funds for upper gastrointestinal cancers.
The promotion has now closed and a winner has now been drawn – Adam Vankempen of NSW.
The promotion offered members of the community the chance to access exclusive discounts, all while doing good and supporting a great cause. With each purchase, supporters received a promotional code which gave them access to exclusive deals, and as an added bonus they were also entered into a major draw for a chance to win $250,000.
Proceeds of the sales supported the work of Pancare to provide support services for patients and families impacted by upper gastrointestinal cancers, and invest into research towards earlier detection and improved treatments. The national exposure that the ‘Support, Save and Win’ promotion brought also supports Pancare’s objective to raise community awareness about these diseases.
Pancare partnered with Adflex Marketing and Loyalty Promotions to run the promotion. Adflex General Manager Ruth Prunty says: ‘It has been a privilege to work alongside the Pancare team and to bring their important message to the Australian community. We are so grateful to have been a part of raising support into continued research to improve treatment options and increase survival rates for all those impacted by these diseases. We look forward to our continued partnership with Pancare.’
Over 12,400 Australians are expected to be diagnosed with an upper gastrointestinal (GI) cancer this year alone. With no early detection tests, limited treatment options, and severely underfunded research, the average five-year survival rate across the five cancers (pancreatic, liver, stomach, biliary and oesophageal cancers) is just 20 per cent. Pancare is the leading organisation supporting families impacted by Upper GI cancers, and funding research that contributes to a doubling of the five-year survival rate across the Upper GI cancers by 2025.
Read more . . .